Laroprovstat vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Laroprovstat
Developed by AstraZeneca
NCT06173570 · Phase 2 · completed
The study randomized 428 participants to four AZD0780 dose groups or matched placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the regulator-accepted lipid measure LDL cholesterol, and all four AZD0780-versus-placebo comparisons were statistically significant in the favorable direction (p<0.001).
Next expected readout: January 2027 · NCT07000136 (registry estimate)
Reported efficacy
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12): AZD0780 1 mg -31.19% (95% CI -37.06--25.32) vs AZD0780 3 mg -33.83% (95% CI -39.78--27.88) vs AZD0780 10 mg -41.09% (95% CI -46.92--35.25) vs AZD0780 30 mg -46.62% (95% CI -52.48--40.76) vs Placebo 4.08% (95% CI -1.84-10.00); p=< 0.001 (AZD0780 1 mg vs Placebo), p=< 0.001 (AZD0780 3 mg vs Placebo), p=< 0.001 (AZD0780 10 mg vs Placebo), p=< 0.001 (AZD0780 30 mg vs Placebo) (met)
Result source: NCT06173570
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomised, quadruple-blind, placebo-controlled trial randomised 618 Chinese patients with non-familial hypercholesterolaemia (614 dosed) and met its primary endpoint: LDL cholesterol fell 57 to 65 percentage points more than with placebo at week 48 across both dosing regimens, a highly statistically significant result.
618 patients were randomised (publication); the registry's actual-enrolment field says 804.
Next expected readout: December 2026 · NCT07341958 (registry estimate)
Reported efficacy
Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48: LDL-C percent change from baseline to week 48, treatment difference vs placebo: -65.0% (97.5% CI: -70.2%, -59.9%) for tafolecimab 450 mg Q4W; -57.3% (97.5% CI: -64.0%, -50.7%) for 600 mg Q6W; both P < 0.0001 (met)
Result source: NCT04289285
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Laroprovstat | Tafolecimab |
|---|---|---|
| LDL-C, % change | -46.6% vs 4.1%−50.7 vs placeboNCT061735707 other results
| -58.7% vs 3.2%a−61.9 vs placeboNCT041796692 other results
|
| Non-HDL-C, % change | -41.6% vs 3.5%−45.2 vs placeboNCT061735707 other results
| —Not posted · NCT04031742 |
| ApoB, % change | -37.0% vs 2.9%−39.9 vs placeboNCT061735707 other results
| —Not posted · NCT04031742 |
| Lp(a), % change | -19.4% vs 0%−19.4 vs placeboNCT061735703 other results
| —Not posted · NCT04031742 |
| 3-point MACE (% with event) | —Trial running · NCT06834932 | —Not posted · NCT04031742 |
LDL-C, % change
- Laroprovstat
- -46.6% vs 4.1%−50.7 vs placeboNCT06173570
7 other results
- -41.1% vs 4.1% NCT06173570
- -33.8% vs 4.1% NCT06173570
- -31.2% vs 4.1% NCT06173570
- -46.4% vs 3.4% NCT06173570
- -40.5% vs 3.4% NCT06173570
- -33.4% vs 3.4% NCT06173570
- -30.5% vs 3.4% NCT06173570
- Tafolecimab
- -58.7% vs 3.2%a−61.9 vs placeboNCT04179669
2 other results
- -58.4% vs -1% NCT04179669
- -68.9% vs -5.8% NCT04709536
Non-HDL-C, % change
- Laroprovstat
- -41.6% vs 3.5%−45.2 vs placeboNCT06173570
7 other results
- -41.4% vs 2.9% NCT06173570
- -35.1% vs 3.5% NCT06173570
- -34.8% vs 2.9% NCT06173570
- -29.9% vs 3.5% NCT06173570
- -29.4% vs 2.9% NCT06173570
- -26.9% vs 3.5% NCT06173570
- -26.1% vs 2.9% NCT06173570
- Tafolecimab
- —Not posted · NCT04031742
ApoB, % change
- Laroprovstat
- -37.0% vs 2.9%−39.9 vs placeboNCT06173570
7 other results
- -36.9% vs 2.4% NCT06173570
- -34.3% vs 2.9% NCT06173570
- -33.9% vs 2.4% NCT06173570
- -25.4% vs 2.9% NCT06173570
- -24.5% vs 2.4% NCT06173570
- -24.1% vs 2.9% NCT06173570
- -23.4% vs 2.4% NCT06173570
- Tafolecimab
- —Not posted · NCT04031742
Lp(a), % change
- Laroprovstat
- -19.4% vs 0%−19.4 vs placeboNCT06173570
3 other results
- -19.6% vs 0% NCT06173570
- -11.2% vs 0% NCT06173570
- -7.5% vs 0% NCT06173570
- Tafolecimab
- —Not posted · NCT04031742
3-point MACE (% with event)
- Laroprovstat
- —Trial running · NCT06834932
- Tafolecimab
- —Not posted · NCT04031742
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Laroprovstat: 4 of 4 rows · Tafolecimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Laroprovstat | Tafolecimab |
|---|---|---|
| Dropout rate | 5.9%30 mga NCT06173570 · Phase 2 show 3 more results1.2%10 mg NCT06173570 · Phase 2 4.7%3 mg NCT06173570 · Phase 2 5.8%1 mg NCT06173570 · Phase 2 | — |
| Discontinued due to AEs | 2.4%30 mga NCT06173570 · Phase 2 show 3 more results0%10 mg NCT06173570 · Phase 2 0%3 mg NCT06173570 · Phase 2 1.2%1 mg NCT06173570 · Phase 2 | — |
| Serious AEs | 1.2%30 mga NCT06173570 · Phase 2 show 3 more results2.4%10 mg NCT06173570 · Phase 2 2.4%3 mg NCT06173570 · Phase 2 2.3%1 mg NCT06173570 · Phase 2 | — |
| Most frequent reported AEs | show 3 more results | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Laroprovstat
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 7 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Laroprovstat's landscape · Tafolecimab's landscape